Abalos Therapeutics is pioneering a novel approach to cancer treatment through its proprietary AdaptInnate platform, which utilizes arenaviruses to stimulate the immune system. This innovative technology is designed to trigger precise innate and adaptive immune responses directly within tumors, effectively engaging various immune cell types to mount a comprehensive attack against both primary tumors and metastatic sites. The lead product candidate, ABX-001, has shown promising anti-tumor efficacy and a favorable safety profile in pre-clinical studies, with plans to enter clinical trials in 2025. This non-oncolytic strategy allows the drug to persist and replicate within cancerous and antigen-presenting cells, promoting targeted and durable anti-tumor activity.

The scientific foundation of Abalos Therapeutics is built on the unique properties of arenaviruses, which are leveraged to create a new class of immuno-oncology therapies. By harnessing the immunostimulatory capabilities of these viruses, Abalos aims to activate the full breadth of the immune response against solid tumors. The company is led by a team of experienced biotech entrepreneurs and immunology experts, all dedicated to advancing this innovative therapeutic approach and establishing a new paradigm in cancer treatment.

Germany

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system's power specifically against cancer cells. Through viral replication within cancer cells, Abalos' arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos' goal is to achieve a quantum leap in immuno-oncology.

Abalos Therapeutics

Company Details